{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.95","upperLimit":"1.02","value":"0.99"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"5.6","value":"0.99"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"description":"Time to response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better).","dispersionType":"Full Range","groups":[{"description":"Daratumumab 8 milligram per kilogram (mg/kg) every 4 weeks (Q4W) until disease progression or unacceptable toxicity.","id":"OG000","title":"Daratumumab 8 mg/kg"},{"description":"Daratumumab 16 mg/kg weekly for 8 weeks; then every 2 weeks (Q2W) for 16 weeks; then Q4W until disease progression or unacceptable toxicity.","id":"OG001","title":"Daratumumab 16 mg/kg"}],"paramType":"MEDIAN","populationDescription":"Responders in all treated analysis set. Only those participants with confirmed PR were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 14.4 Months","title":"Time to Response","type":"SECONDARY","unitOfMeasure":"months"}